BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin ( Oz-V ) in Oropharyngeal Squamous Cell Carcinoma ( OPSCC ) at the Annual Conference of the International Papillomavirus Society

Benzinga
2025.10.23 12:40
portai
I'm PortAI, I can summarize articles.

聖地亞哥，2025 年 10 月 23 日（GLOBE NEWSWIRE）-- BioAtla, Inc.（納斯達克：BCAB），一家全球臨牀階段生物技術公司，專注於開發條件性活性生物（CAB）抗體治療用於治療實體腫瘤，今天宣佈將展示一份海報

Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.